Enhanced anti-tumor activity of this combination is based on multiple mechanisms, including enhanced inhibition of phosphorylation of AURKA, PAK1, and ERα, as well as decreased expression of cell cycle proteins and C-MYC. The gene discussed is AURKA; the disease is neoplasm.